Molecular characterization featuring our proprietary Trailblaze Pharos™ assay
What does this mean for Oncologists and other Health Care Providers?
Our companion diagnostics approach pairs the Trailblaze Pharos™ comprehensive diagnostic assay with a promising investigational precision therapy for trial participants.
It is provided at no-cost to ordering physicians.
Expand your clinical toolkit to include the Trailblaze Pharos™ molecular test.
More about Trailblaze Pharos™ Cancer Diagnostics
Specimens undergo Next-Generation Sequencing (using a custom Archer® FusionPlex® panel) to identify whether rearrangements in the genes of interest are present.1
Results are communicated in a clear format that takes the guesswork out of interpretation.
A detailed report will be provided to the ordering physician within two to three weeks of sample receipt.
This rigorous screening step streamlines the decision making process by identifying those patients who may be eligible for enrollment in the STARTRK-2 trial and potentially derive benefit from investigational entrectinib treatment.
Ignyta covers the costs of diagnostic testing for all patient specimens; you can utilize this technology at no-cost to your practice. Our logistics team will:
Provide packaging and shipping materials
Retrieve existing biopsy samples
Provide the diagnostic result within two to three weeks of receipt of the tissue specimen at Ignyta's CAP-accredited central diagnostics lab
View a sample Trailblaze® Report
Identifying information: The Ignyta Diagnostic Lab is fully CAP, HIPAA and QSR compliant
Clinical Data: Previous information about the patient's disease is summarized here for reference at-a-glance
Result: Results of molecular and genetic testing for cancer biomarkers are presented in a clear, unbiased way. This format empowers the ordering physician to make a confident decision to proceed with continuing the enrollment process.
1 Murphy et al. Appl Immunohistochem Mol Morphol 2016
This test was developed and its performance characteristics determined by Ignyta, Inc. It has not been cleared or approved by the FDA. The laboratory is regulated under the CLIA as qualified to perform high-complexity testing.